An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910